No biomarker
|
Adrenal Cortex Carcinoma
|
No biomarker
|
Adrenal Cortex Carcinoma
|
mitotane Sensitive: A1 - Approval
|
mitotane Sensitive: A1 - Approval
|
No biomarker
|
Adrenal Cortex Carcinoma
|
No biomarker
|
Adrenal Cortex Carcinoma
|
cisplatin + carboplatin + etoposide IV + mitotane + SGN-15 Sensitive: A2 - Guideline
|
cisplatin + carboplatin + etoposide IV + mitotane + SGN-15 Sensitive: A2 - Guideline
|
No biomarker
|
Adrenal Cortex Carcinoma
|
No biomarker
|
Adrenal Cortex Carcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Adrenal Cortex Carcinoma
|
No biomarker
|
Adrenal Cortex Carcinoma
|
cisplatin Sensitive: A2 - Guideline
|
cisplatin Sensitive: A2 - Guideline
|
No biomarker
|
Adrenal Cortex Carcinoma
|
No biomarker
|
Adrenal Cortex Carcinoma
|
cisplatin + etoposide IV Sensitive: A2 - Guideline
|
cisplatin + etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Adrenal Cortex Carcinoma
|
No biomarker
|
Adrenal Cortex Carcinoma
|
cisplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive: A2 - Guideline
|
cisplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive: A2 - Guideline
|
No biomarker
|
Adrenal Cortex Carcinoma
|
No biomarker
|
Adrenal Cortex Carcinoma
|
carboplatin + etoposide IV + mitotane Sensitive: A2 - Guideline
|
carboplatin + etoposide IV + mitotane Sensitive: A2 - Guideline
|
No biomarker
|
Adrenal Cortex Carcinoma
|
No biomarker
|
Adrenal Cortex Carcinoma
|
carboplatin + doxorubicin hydrochloride + etoposide IV Sensitive: A2 - Guideline
|
carboplatin + doxorubicin hydrochloride + etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Adrenal Cortex Carcinoma
|
No biomarker
|
Adrenal Cortex Carcinoma
|
carboplatin + etoposide IV Sensitive: A2 - Guideline
|
carboplatin + etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Adrenal Cortex Carcinoma
|
No biomarker
|
Adrenal Cortex Carcinoma
|
carboplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive: A2 - Guideline
|
carboplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive: A2 - Guideline
|
No biomarker
|
Adrenal Cortex Carcinoma
|
No biomarker
|
Adrenal Cortex Carcinoma
|
cisplatin + etoposide IV + mitotane Sensitive: A2 - Guideline
|
cisplatin + etoposide IV + mitotane Sensitive: A2 - Guideline
|
No biomarker
|
Adrenal Cortex Carcinoma
|
No biomarker
|
Adrenal Cortex Carcinoma
|
cisplatin + doxorubicin hydrochloride + etoposide IV Sensitive: A2 - Guideline
|
cisplatin + doxorubicin hydrochloride + etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Adrenal Cortex Carcinoma
|
No biomarker
|
Adrenal Cortex Carcinoma
|
streptozocin Sensitive: A2 - Guideline
|
streptozocin Sensitive: A2 - Guideline
|
No biomarker
|
Adrenal Cortex Carcinoma
|
No biomarker
|
Adrenal Cortex Carcinoma
|
mitotane + streptozocin Sensitive: A2 - Guideline
|
mitotane + streptozocin Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Adrenal Cortex Carcinoma
|
MSI-H/dMMR
|
Adrenal Cortex Carcinoma
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
RRM1 underexpression
|
Adrenal Cortex Carcinoma
|
RRM1 underexpression
|
Adrenal Cortex Carcinoma
|
mitotane Sensitive: C3 – Early Trials
|
mitotane Sensitive: C3 – Early Trials
|
TMB-L
|
Adrenal Cortex Carcinoma
|
TMB-L
|
Adrenal Cortex Carcinoma
|
mitotane Sensitive: C3 – Early Trials
|
mitotane Sensitive: C3 – Early Trials
|
MSH2 mutation
|
Adrenal Cortex Carcinoma
|
MSH2 mutation
|
Adrenal Cortex Carcinoma
|
pembrolizumab Sensitive: C4 – Case Studies
|
pembrolizumab Sensitive: C4 – Case Studies
|
FGFR3-TACC3 fusion
|
Adrenal Cortex Carcinoma
|
FGFR3-TACC3 fusion
|
Adrenal Cortex Carcinoma
|
erdafitinib Sensitive: C4 – Case Studies
|
erdafitinib Sensitive: C4 – Case Studies
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
rubitecan Sensitive: D – Preclinical
|
rubitecan Sensitive: D – Preclinical
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
teniposide Sensitive: D – Preclinical
|
teniposide Sensitive: D – Preclinical
|
CDK1 overexpression
|
Adrenal Cortex Carcinoma
|
CDK1 overexpression
|
Adrenal Cortex Carcinoma
|
DSP-2033 Sensitive: D – Preclinical
|
DSP-2033 Sensitive: D – Preclinical
|
CDK4 overexpression
|
Adrenal Cortex Carcinoma
|
CDK4 overexpression
|
Adrenal Cortex Carcinoma
|
palbociclib Sensitive: D – Preclinical
|
palbociclib Sensitive: D – Preclinical
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
etoposide oral Sensitive: D – Preclinical
|
etoposide oral Sensitive: D – Preclinical
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
pirarubicin Sensitive: D – Preclinical
|
pirarubicin Sensitive: D – Preclinical
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
mitoxantrone Sensitive: D – Preclinical
|
mitoxantrone Sensitive: D – Preclinical
|
AURKA overexpression
|
Adrenal Cortex Carcinoma
|
AURKA overexpression
|
Adrenal Cortex Carcinoma
|
SA033 + AMG 900 Sensitive: D – Preclinical
|
SA033 + AMG 900 Sensitive: D – Preclinical
|
AURKB overexpression
|
Adrenal Cortex Carcinoma
|
AURKB overexpression
|
Adrenal Cortex Carcinoma
|
SA033 + AMG 900 Sensitive: D – Preclinical
|
SA033 + AMG 900 Sensitive: D – Preclinical
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
idarubicin hydrochloride Sensitive: D – Preclinical
|
idarubicin hydrochloride Sensitive: D – Preclinical
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
SA033 Sensitive: D – Preclinical
|
SA033 Sensitive: D – Preclinical
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
daunorubicin Sensitive: D – Preclinical
|
daunorubicin Sensitive: D – Preclinical
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
TOP2A overexpression
|
Adrenal Cortex Carcinoma
|
aclarubicin Sensitive: D – Preclinical
|
aclarubicin Sensitive: D – Preclinical
|
AURKB overexpression
|
Adrenal Cortex Carcinoma
|
AURKB overexpression
|
Adrenal Cortex Carcinoma
|
mitotane + AMG 900 Sensitive: D – Preclinical
|
mitotane + AMG 900 Sensitive: D – Preclinical
|
AURKA overexpression
|
Adrenal Cortex Carcinoma
|
AURKA overexpression
|
Adrenal Cortex Carcinoma
|
mitotane + AMG 900 Sensitive: D – Preclinical
|
mitotane + AMG 900 Sensitive: D – Preclinical
|
AURKA overexpression
|
Adrenal Cortex Carcinoma
|
AURKA overexpression
|
Adrenal Cortex Carcinoma
|
AMG 900 Sensitive: D – Preclinical
|
AMG 900 Sensitive: D – Preclinical
|
AURKB overexpression
|
Adrenal Cortex Carcinoma
|
AURKB overexpression
|
Adrenal Cortex Carcinoma
|
AMG 900 Sensitive: D – Preclinical
|
AMG 900 Sensitive: D – Preclinical
|
MET overexpression
|
Adrenal Cortex Carcinoma
|
MET overexpression
|
Adrenal Cortex Carcinoma
|
cabozantinib capsule Sensitive: D – Preclinical
|
cabozantinib capsule Sensitive: D – Preclinical
|
CDK2 overexpression
|
Adrenal Cortex Carcinoma
|
CDK2 overexpression
|
Adrenal Cortex Carcinoma
|
DSP-2033 Sensitive: D – Preclinical
|
DSP-2033 Sensitive: D – Preclinical
|
EZH2 overexpression
|
Adrenal Cortex Carcinoma
|
EZH2 overexpression
|
Adrenal Cortex Carcinoma
|
mitotane + EZH2 inhibitor Sensitive: D – Preclinical
|
mitotane + EZH2 inhibitor Sensitive: D – Preclinical
|
ASXL1 overexpression
|
Adrenal Cortex Carcinoma
|
ASXL1 overexpression
|
Adrenal Cortex Carcinoma
|
EDP Resistant: D – Preclinical
|
EDP Resistant: D – Preclinical
|